Diaceutics and PCC launch NGS Concordance Study
Summary by AI BETAClose X
RNS Reach
Diaceutics PLC
Diaceutics and PCC launch NGS Concordance Study to advance precision oncology and support informed biomarker testing
This collaborative industry initiative will assess concordance in variant detection across next-generation sequencing (NGS) panels and platforms used in routine clinical practice
The study will generate evidence to strengthen transparency, confidence, and quality in informed biomarker testing to maximize patient access to personalized care
New York, Belfast and London, 20 August 2026 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry and the Precision Cancer Consortium (PCC) today announced the launch of a new NGS Concordance Study designed to evaluate variation in variant detection across NGS panels and platforms used in routine clinical practice. Through this collaboration, the organizations aim to generate evidence on testing concordance, improve understanding of testing variability, and unite precision medicine stakeholders to advance confidence in oncology diagnostics and biomarker testing.
"Precision medicine depends on the quality and consistency of diagnostic testing," said Susanne Munksted, Chief Precision Medicine Officer at Diaceutics. "As the number and complexity of NGS panels continue to grow, it is increasingly important that laboratories, diagnostics companies, and the wider precision oncology community work together to better understand testing variability and generate evidence that strengthens confidence in biomarker testing. This study represents an important opportunity to advance that understanding and support better outcomes for patients."
The study builds on growing recognition of the need for greater transparency and confidence in biomarker testing. Findings from Diaceutics' Clinical Practice Gaps in Precision Medicine research showed encouraging improvements in biomarker testing performance, while also highlighting the growing complexity of the diagnostics landscape and the need to better understand how testing approaches perform in routine clinical practice. As NGS testing becomes central to identifying patients for targeted therapies, understanding how different panels and platforms perform in routine practice has become an important focus for the industry.
"No single organization can address the challenges facing precision oncology alone. By bringing together expertise from across the healthcare ecosystem, this collaboration aims to generate evidence that improves understanding of testing concordance and supports informed biomarker testing," said John Longshore, Chair of the PCC. "Through initiatives such as the NGS concordance study, the PCC continues to advance its mission of improving access to high-quality biomarker testing and helping more patients benefit from precision oncology."
Key study objectives
- Evaluate up to 20 NGS assays currently used in routine clinical practice across US laboratories
- Assess concordance by comparing identified genomic variants against known reference profiles within synthetic samples
- Improve understanding of variability across different NGS panels and testing platforms
- Generate evidence to support future scientific publications, conference presentations, and industry discussions
- Foster collaboration between precision medicine stakeholders including pharmaceutical providers, laboratories, and diagnostics companies to advance confidence in oncology testing
- Advance understanding of concordance across routine NGS panels and inform future discussions on testing quality, transparency, and best practice in precision oncology
Industry collaboration opportunity
Diaceutics and PCC welcome engagement from laboratories, diagnostic companies, and precision medicine stakeholders supporting an industry-wide effort to understand testing concordance, build confidence in cancer diagnostics, and highlight the importance of test selection in patient identification. By participating in the study, organizations can contribute to collaborative evidence generation that supports improvements in testing performance, transparency and quality across precision oncology.
About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialization solution for precision medicines through data analytics, and scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.
About the Precision Cancer Consortium (PCC)
The PCC is a consortium of pharmaceutical companies dedicated to advancing precision oncology through collective action. By bringing together expertise from across the healthcare ecosystem, the PCC is dedicated to a future where every person with cancer-regardless of who they are or where they live-can benefit from precision oncology. Through global collaboration, we work to make biomarker-informed, data-driven patient identification and personalized care standard practice.
Enquiries:
|
Diaceutics PLC |
|
|
Ryan Keeling, Chief Executive Officer |
Tel: +44 (0)28 9040 6500 |
|
Nick Roberts, Chief Financial Officer |
investorrelations@diaceutics.com |
|
|
|
|
Canaccord Genuity Limited (Nomad & Broker) |
Tel: +44 (0)20 7253 8000 |
|
Simon Bridges, Andrew Potts, Harry Rees |
|
For further information about the PCC, visit:
https://www.precisioncancerconsortium.com
Media Contact
Arian Vahidansari
Indigo Medical, on behalf of the Precision Cancer Consortium (PCC)
arian.vahidansari@indigomedical.co.uk
Phone: +44 7415 125 031
About Reach Announcements
Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate, and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 55 minutes ago CAP-XX Limited
- 55 minutes ago Prudential
- 55 minutes ago Duke Royalty Limited
- 55 minutes ago Barr (A.G.)
- 55 minutes ago Hargreaves Services